These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32897829)

  • 1. Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    Schweizer MT; Cheng HH; Nelson PS; Montgomery RB
    J Clin Oncol; 2020 Nov; 38(32):3740-3742. PubMed ID: 32897829
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 3. PARP inhibitors in castration-resistant prostate cancer.
    Tripathi A; Balakrishna P; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors for ovarian cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
    [No Abstract]   [Full Text] [Related]  

  • 8. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
    Helleday T
    Ann Oncol; 2016 May; 27(5):755-7. PubMed ID: 26865580
    [No Abstract]   [Full Text] [Related]  

  • 9. [The PROfound study or the arrival of personalised medicine in the treatment of prostate cancer].
    Houédé N
    Bull Cancer; 2021 May; 108(5):448. PubMed ID: 33722378
    [No Abstract]   [Full Text] [Related]  

  • 10. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibition in BRCA2-mutated prostate cancer.
    Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
    [No Abstract]   [Full Text] [Related]  

  • 12. Olaparib provides benefit in metastatic breast cancer.
    Das M
    Lancet Oncol; 2017 Jul; 18(7):e376. PubMed ID: 28602780
    [No Abstract]   [Full Text] [Related]  

  • 13. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    Hilmi M; Neuzillet C
    Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
    [No Abstract]   [Full Text] [Related]  

  • 14. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    Kwon DH; Booth CM; Prasad V
    Eur Urol; 2021 Jun; 79(6):710-712. PubMed ID: 33722420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitors in Prostate Cancer.
    Grewal K; Grewal K; Tabbara IA
    Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
    N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
    VanderWeele DJ; Hussain M
    Clin Adv Hematol Oncol; 2020 Dec; 18(12):808-815. PubMed ID: 33406057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
    Zhu J; Tucker M; Wang E; Grossman JS; Armstrong AJ; George DJ; Zhang T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1137-e1141. PubMed ID: 28780018
    [No Abstract]   [Full Text] [Related]  

  • 19. PARP inhibition - not all gene mutations are created equal.
    Luo J; Antonarakis ES
    Nat Rev Urol; 2019 Jan; 16(1):4-6. PubMed ID: 30498248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
    Mateo J; Porta N; Bianchini D; McGovern U; Elliott T; Jones R; Syndikus I; Ralph C; Jain S; Varughese M; Parikh O; Crabb S; Robinson A; McLaren D; Birtle A; Tanguay J; Miranda S; Figueiredo I; Seed G; Bertan C; Flohr P; Ebbs B; Rescigno P; Fowler G; Ferreira A; Riisnaes R; Pereira R; Curcean A; Chandler R; Clarke M; Gurel B; Crespo M; Nava Rodrigues D; Sandhu S; Espinasse A; Chatfield P; Tunariu N; Yuan W; Hall E; Carreira S; de Bono JS
    Lancet Oncol; 2020 Jan; 21(1):162-174. PubMed ID: 31806540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.